Description

Human Histaglobulin (Min’ErKang) comprises purified human immunoglobulin combined with histamine phosphate in a defined ratio. After reconstitution, the injection is used to induce anti-histamine antibodies and modulate allergic responses. This formulation models passive immunotherapy in preclinical research on chronic urticaria, asthma, atopic dermatitis, and allergy immunoregulation. Manufactured under approval S19993062 by a reputable Chinese biopharma company. Supplied exclusively for laboratory research use. Each box contains ten vials of 12?mg/2?ml each.

Product Specifications

Mechanism of Action & Research Applications

Human Histaglobulin (Min’ErKang) delivers pooled human IgG complexed with histamine to stimulate anti-histamine antibody production and modulate immune responses. Clinical research shows weekly injections can achieve significant long?term remission of chronic spontaneous urticaria and reduce antihistamine dependency by up to 80% within eight weeks. In preclinical research, this product is used to model allergy immunotherapy, simulate passive immunity, study IgG?histamine interactions, and explore tolerance induction protocols. Results guide design of immunomodulatory and allergy-focused experimental studies. For laboratory research use only.

Side Effects (For Reference Only in Models)

In experimental or analogous clinical settings, observed reactions may include minor injection-site redness, transient fever, mild allergic responses, or urticaria flare. Laboratory reports indicate high tolerability with rare adverse outcomes. Researchers should monitor responses in dose-escalation protocols and model selection.

Disclaimer

Human Histaglobulin (Min’ErKang) 12?mg (2?ml) is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.